Skip to content

Author

Tong-Yong Luo

We have 5 of 20 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Sep 2026

ASF1A: A versatile histone chaperone bridging chromatin dynamics, disease mechanisms and clinical potential (Review)

Anti-silencing function 1A (ASF1A) is an evolutionarily conserved histone H3/H4 chaperone that mediates nucleosome assembly, DNA replication and DNA damage repair. Beyond these canonical biological functions, aberrant ASF1A expression facilitates disease progression by triggering epigenetic dysregulation in multiple ma...

Jun Yin, Xiao-Jian Zhuo, Li-Hui Wen et al. · 0 citations
Review Open access Jul 2026

The role of OTUD1-mediated deubiquitination in disease pathogenesis: from molecular mechanisms to clinical translation

OTUD1 is a deubiquitinase of the OTU family that participates in immune signaling, redox balance, and cell death through modulating substrate ubiquitination. Under physiological conditions, OTUD1 primarily exerts negative regulatory effects, restricting excessive activation of NF-κB inflammatory signaling and type I in...

Qing-Song Wang, Lijuan Zhang, Hong-Mei Cao et al. · 0 citations
Review Open access Jul 2026

Targeting the deubiquitinase USP28 in cancer: navigating context-dependent mechanisms and therapeutic resistance

A review of the molecular characteristics and physiological functions of USP28, its context-dependent roles in neoplastic diseases, and its translational implications for targeted therapy and biomarker discovery highlights its potential as a therapeutic target for precision medicine.

Tong-Yong Luo, Shuncai Wu, Qing-Song Wang et al. · 1 citation
Review Open access Jul 2026

RNA-binding protein RBM47 in health and disease: molecular mechanisms, preclinical evidence, and translational challenges

The molecular characteristics and pathological mechanisms of RBM47 are summarized, the preclinical rationale for its potential utility as a biomarker and therapeutic node is discussed, and current research limitations, conflicting evidence, and translational bottlenecks are critically analyzed.

Shihua Huang, Qingsong Wang, Junhong Shen et al. · 0 citations
Review Open access Jul 2026

The RNA-binding protein CELF4: from molecular regulatory networks to clinical translation in cross-system diseases

The molecular regulatory networks of CELF4 and its mechanisms across multisystem diseases are reviewed, the current status and limitations of clinical translation are discussed, and future research on diagnostic biomarkers and therapeutic strategies targeting this protein is guided.

Qingsong Wang, Wenlong Yue, D. Lin et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.